NASDAQ$ENGN

enGene Therapeutics Inc · Q1 2026 earnings

Q1 2026 earnings · · Before market open · Investor relations

Briefing

ENGN reported Q1 2026, net loss of $30M.

For Q1 2026, ENGN reported a net loss of $30M. Management discusses segment performance, capital allocation, and macro risks in the quarterly filing.

  • Net loss $30M.
  • ENGN MD&A covers liquidity, credit, and operating priorities.
  • ENGN MD&A covers liquidity, credit, and operating priorities.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS

$0.44

Previous: $0.48-8.3%
G&A Expenses

$8.93M

Previous: $6.64M+34.5%
Total Operating Expenses

$31.2M

Previous: $26.6M+17.2%
Net Loss per Share

$0.44

Previous: $0.48-8.3%
Weighted Avg Shares

67.3M

Previous: 51.0M+31.9%
R&D Expenses

$22.3M

Previous: $20M+11.4%
Capital Expenditures

-$153K

Previous: -$299K+48.8%
Free Cash Flow

-$29.1M

Previous: -$26M-11.8%
Net Income

-$29.8M

Previous: -$24.6M-20.9%
Operating Income

-$31.2M

Previous: -$26.6M-17.2%
Gross Profit

-$50K

Previous: -$50K+0.0%
Cash & Equivalents

$36.6M

Previous: $62.3M-41.3%
Total Assets

$337M

Previous: $286M+17.9%

Revenue & EPS history

Engene · Revenue · Quarterly

$0

Q1 2026

Forward guidance

The quarterly filing discusses operating priorities, capital returns, and sector risks.

Tailwinds

  • MD&A highlights liquidity and core business trends.
  • Segment commentary supports the earnings narrative.

Headwinds

  • Macro or input-cost pressure may affect margins.
  • One-time items can affect YoY comparability.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 14 quarterly earnings reports · overlaid with Q1 2026

Historical avgQ1 2026

-2.6%

Avg return

Earnings day

-1.6%

Avg return

5 days after

+17.4%

Avg return

30 days after

43%

6 / 14 earnings

Positive

+5.3%

Q4 2025

Best reaction

-18.9%

Q1 2026

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026
Q1 2026-18.9%-17.5%-15.8%
Q4 2025+5.3%+8.3%+21.3%
Q3 2025-6.3%+7.6%+38.4%
Q2 2025-0.9%+0.9%+2.8%
Q1 2025+4.9%-10.1%-22.3%
Q4 2024-1.7%+6.6%+20.4%
Q3 2023+1.8%+1.7%+4.3%
Q3 2024+1.8%+1.7%+4.3%
Q2 2024-13.5%-16.4%-9.3%
Q2 2023-13.5%-16.4%-9.3%
Q1 2024+4.9%+5.2%-1.6%
Q1 2023+4.9%+5.2%-1.6%
Q4 2023-2.7%+0.5%+106.1%
Q4 2022-2.7%+0.5%+106.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro